Literature DB >> 8052311

Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor.

G M McGeehan1, J D Becherer, R C Bast, C M Boyer, B Champion, K M Connolly, J G Conway, P Furdon, S Karp, S Kidao.   

Abstract

Tumour necrosis factor-alpha (TNF-alpha) is a potent pro-inflammatory agent produced primarily by activated monocytes and macrophages. TNF-alpha is synthesized as a precursor protein of M(r) 26,000 (26K) which is processed to a secreted 17K mature form by cleavage of an Ala-Val bond between residues 76-77. The enzyme(s) responsible for processing pro-TNF-alpha has yet to be identified. Here, we describe the capacity of a metalloproteinase inhibitor, GI 129471, to block TNF-alpha secretion both in vitro and in vivo. The inhibition is specific to TNF-alpha; the production of other secreted cytokines, such as the interleukins IL-1 beta, IL-2, or IL-6, is not inhibited. The mechanism of inhibition occurs at a post-translational step in TNF-alpha production. Our data suggest that TNF-alpha processing is mediated by a unique Zn2+ endopeptidase which is inhibited by GI 129471 and would represent a novel target for therapeutic intervention in TNF-alpha associated pathologies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8052311     DOI: 10.1038/370558a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  95 in total

Review 1.  Biologic therapies in rheumatoid arthritis.

Authors:  K J Bulpitt
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

Review 2.  The role of anti-cytokine therapy in the failing heart.

Authors:  A Deswal; A Misra; B Bozkurt
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

3.  The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans.

Authors:  P E Dekkers; T ten Hove; F N Lauw; H R Koene; P Lumley; S J van Deventer; T van der Poll
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

Review 4.  Matrix metalloproteinase biology applied to vitreoretinal disorders.

Authors:  C S Sethi; T A Bailey; P J Luthert; N H Chong
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

Review 5.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

6.  Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases.

Authors:  Juan Carlos Montero; Laura Yuste; Elena Díaz-Rodríguez; Azucena Esparís-Ogando; Atanasio Pandiella
Journal:  Biochem J       Date:  2002-04-15       Impact factor: 3.857

7.  Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. Evidence that monocyte/macrophage progenitors may be responsible for TNFalpha overproduction.

Authors:  E Carballo; G S Gilkeson; P J Blackshear
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

8.  Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.

Authors:  Paul A Lapchak; Qiang Wu
Journal:  J Neurol Neurophysiol       Date:  2011

Review 9.  The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling.

Authors:  Joseph S Janicki; Gregory L Brower; Jason D Gardner; Amanda L Chancey; James A Stewart
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

Review 10.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.